Heterogeneity of glycolysis in cancers and therapeutic opportunities.

[1]  Xiling Shen,et al.  Epigenetics and cancer metabolism. , 2015, Cancer letters.

[2]  A. Scheck,et al.  The ketogenic diet for the treatment of malignant glioma , 2015, Journal of Lipid Research.

[3]  U. Sauer,et al.  Advancing metabolic models with kinetic information. , 2014, Current opinion in biotechnology.

[4]  T. Copetti,et al.  Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration , 2014, Oncogene.

[5]  G. Lou,et al.  A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. , 2014, Molecular bioSystems.

[6]  A. Shehzad,et al.  Role of AMP‐Activated Protein Kinase in Cancer Therapy , 2014, Archiv der Pharmazie.

[7]  Prodromos Daoutidis,et al.  Bistability in Glycolysis Pathway as a Physiological Switch in Energy Metabolism , 2014, PloS one.

[8]  M. Reginato,et al.  O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. , 2014, Molecular cell.

[9]  Xin Yu,et al.  3-Bromopyruvic acid, a hexokinase II inhibitor, is an effective antitumor agent on the hepatoma cells : in vitro and in vivo findings. , 2014, Anti-cancer agents in medicinal chemistry.

[10]  Hao Wu,et al.  Beyond Warburg effect – dual metabolic nature of cancer cells , 2014, Scientific Reports.

[11]  A. Thompson.  Molecular Pathways Molecular Pathways : Preclinical Models and Clinical Trials with Metformin in Breast Cancer , 2014 .

[12]  Jens C. Brüning,et al.  Regulation of metabolism by long, non-coding RNAs , 2014, Front. Genet..

[13]  Keisuke Ito,et al.  Metabolic requirements for the maintenance of self-renewing stem cells , 2014, Nature Reviews Molecular Cell Biology.

[14]  M. Ohmura,et al.  Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway , 2014, Nature Communications.

[15]  Zachary W. Dwyer,et al.  SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. , 2014, Molecular cell.

[16]  Prahlad T. Ram,et al.  Cancer Systems Biology: a peek into the future of patient care? , 2014, Nature Reviews Clinical Oncology.

[17]  E. Wanker,et al.  HIF1α Modulates Cell Fate Reprogramming Through Early Glycolytic Shift and Upregulation of PDK1–3 and PKM2 , 2014, Stem cells.

[18]  T. Bullock,et al.  Metabolic Influences That Regulate Dendritic Cell Function in Tumors , 2014, Front. Immunol..

[19]  C. Barbas,et al.  Metabolomics in cancer biomarker discovery: current trends and future perspectives. , 2014, Journal of pharmaceutical and biomedical analysis.

[20]  P. Carmeliet,et al.  Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. , 2014, Cell metabolism.

[21]  P. Carmeliet,et al.  Incomplete and transitory decrease of glycolysis , 2014, Cell cycle.

[22]  P. Carmeliet,et al.  Control of vessel sprouting by genetic and metabolic determinants , 2013, Trends in Endocrinology & Metabolism.

[23]  María Martín,et al.  Activities at the Universal Protein Resource (UniProt) , 2013, Nucleic Acids Res..

[24]  V. Bucci,et al.  Emergence of spatial structure in the tumor microenvironment due to the Warburg effect , 2013, Proceedings of the National Academy of Sciences.

[25]  P. Carmeliet,et al.  Role of endothelial cell metabolism in vessel sprouting. , 2013, Cell metabolism.

[26]  R. Meshram,et al.  Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. , 2013, Progress in biophysics and molecular biology.

[27]  N. Hay,et al.  Hexokinase 2 as oncotarget , 2013, Oncotarget.

[28]  Chih-Hao Chang,et al.  Fueling Immunity: Insights into Metabolism and Lymphocyte Function , 2013, Science.

[29]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[30]  Changhua Wang,et al.  Differential phosphofructokinase-1 isoenzyme patterns associated with glycolytic efficiency in human breast cancer and paracancer tissues , 2013, Oncology letters.

[31]  Jie Li,et al.  PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells , 2013, Cell.

[32]  Tomoyoshi Soga,et al.  Oncometabolites: linking altered metabolism with cancer. , 2013, The Journal of clinical investigation.

[33]  J. Cleveland,et al.  Targeting lactate metabolism for cancer therapeutics. , 2013, The Journal of clinical investigation.

[34]  Brendan J. Quinn,et al.  Repositioning metformin for cancer prevention and treatment , 2013, Trends in Endocrinology & Metabolism.

[35]  Abhishek K. Jha,et al.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.

[36]  Fabio Pellegrini,et al.  Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review , 2013, PloS one.

[37]  B. Cravatt,et al.  Functional Lysine Modification by an Intrinsically Reactive Primary Glycolytic Metabolite , 2013, Science.

[38]  Jamey D. Young,et al.  Mapping cancer cell metabolism with13C flux analysis: Recent progress and future challenges , 2013, Journal of carcinogenesis.

[39]  R. Bamezai,et al.  Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2 , 2013, Molecular Cancer.

[40]  Richard D. Beger,et al.  A Review of Applications of Metabolomics in Cancer , 2013, Metabolites.

[41]  J. Locasale.  Serine, glycine and one-carbon units: cancer metabolism in full circle , 2013, Nature Reviews Cancer.

[42]  R. Aebersold,et al.  Western Blots versus Selected Reaction Monitoring Assays: Time to Turn the Tables? , 2013, Molecular & Cellular Proteomics.

[43]  Brian J. Smith,et al.  Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts , 2013, Clinical Cancer Research.

[44]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[45]  Tanja Fehm,et al.  Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer , 2013, Molecular oncology.

[46]  J. Trent,et al.  Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer , 2013, Molecular Cancer Therapeutics.

[47]  F. Khuri,et al.  Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation , 2013, Nature Communications.

[48]  D. Vitkup,et al.  Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.

[49]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[50]  M. Warmoes,et al.  Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance* , 2013, Molecular & Cellular Proteomics.

[51]  A. Schulze,et al.  Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism , 2013, Cancer & metabolism.

[52]  Jennifer L Greene,et al.  Nitric Oxide Regulates Mitochondrial Fatty Acid Metabolism Through Reversible Protein S-Nitrosylation , 2013, Science Signaling.

[53]  W. Sellers,et al.  M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth , 2012, Proceedings of the National Academy of Sciences.

[54]  Taro Hitosugi,et al.  Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. , 2012, Cancer cell.

[55]  E. Petricoin,et al.  Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry. , 2012, Cancer genomics & proteomics.

[56]  Jason W. Locasale,et al.  The consequences of enhanced cell-autonomous glucose metabolism , 2012, Trends in Endocrinology & Metabolism.

[57]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[58]  Eyal Gottlieb,et al.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.

[59]  A. Goldhirsch,et al.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[61]  P. Goodwin,et al.  Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study , 2012, Breast Cancer Research and Treatment.

[62]  Linda C Hsieh-Wilson,et al.  Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism , 2012, Science.

[63]  E. Gottlieb,et al.  Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. , 2012, Trends in biochemical sciences.

[64]  F. Minutolo,et al.  Anticancer Agents That Counteract Tumor Glycolysis , 2012, ChemMedChem.

[65]  Jin-jian Lu,et al.  Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.

[66]  C. Dang.  Links between metabolism and cancer. , 2012, Genes & development.

[67]  G. Melillo,et al.  Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia , 2012, Nature Reviews Clinical Oncology.

[68]  Uwe Sauer,et al.  The importance of post-translational modifications in regulating Saccharomyces cerevisiae metabolism. , 2012, FEMS yeast research.

[69]  M. Shoshan.  3-bromopyruvate: Targets and outcomes , 2012, Journal of Bioenergetics and Biomembranes.

[70]  L. Samson,et al.  Balancing repair and tolerance of DNA damage caused by alkylating agents , 2012, Nature Reviews Cancer.

[71]  M. Birnbaum,et al.  PPARγ contributes to PKM2 and HK2 expression in fatty liver , 2012, Nature Communications.

[72]  P. Singh,et al.  Regulation of Aerobic Glycolysis by microRNAs in Cancer. , 2011, Molecular and cellular pharmacology.

[73]  J. Denu,et al.  Regulation of Glycolytic Enzyme Phosphoglycerate Mutase-1 by Sirt1 Protein-mediated Deacetylation♦ , 2011, The Journal of Biological Chemistry.

[74]  B. Martín-Castillo,et al.  Metformin: Multi-faceted protection against cancer , 2011, Oncotarget.

[75]  Bin Zhang,et al.  PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..

[76]  Xu Dong Zhou,et al.  Arsenic, cadmium and neuron specific enolase (ENO2, γ-enolase) expression in breast cancer , 2011, Cancer Cell International.

[77]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[78]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[79]  Jason W Locasale,et al.  Metabolic flux and the regulation of mammalian cell growth. , 2011, Cell metabolism.

[80]  Zhong Wang,et al.  Next-generation transcriptome assembly , 2011, Nature Reviews Genetics.

[81]  Zhike Lu,et al.  The First Identification of Lysine Malonylation Substrates and Its Regulatory Enzyme* , 2011, Molecular & Cellular Proteomics.

[82]  Gerald W. Hart,et al.  O-GlcNAc signalling: implications for cancer cell biology , 2011, Nature Reviews Cancer.

[83]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[84]  Mélanie Schmidt,et al.  Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial , 2011, Nutrition & metabolism.

[85]  B. Nelson,et al.  A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. , 2011, Cancer research.

[86]  S. Mazurek.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. , 2011, The international journal of biochemistry & cell biology.

[87]  G. Hart,et al.  Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. , 2011, Annual review of biochemistry.

[88]  Emma Saavedra,et al.  Modeling cancer glycolysis. , 2011, Biochimica et biophysica acta.

[89]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[90]  P. Carmeliet,et al.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? , 2011, Nature Reviews Clinical Oncology.

[91]  M. Legiša,et al.  Posttranslational Modification of 6-phosphofructo-1-kinase as an Important Feature of Cancer Metabolism , 2011, PloS one.

[92]  Lei Xie,et al.  Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.

[93]  M. Capello,et al.  α‐enolase: a promising therapeutic and diagnostic tumor target , 2011, The FEBS journal.

[94]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[95]  Q. Lu,et al.  Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. , 2011, International journal of oncology.

[96]  Carlos A. Tristan,et al.  The diverse functions of GAPDH: views from different subcellular compartments. , 2011, Cellular signalling.

[97]  J. Gagliardino,et al.  Liver glucokinase: An overview on the regulatorymechanisms of its activity , 2011, IUBMB life.

[98]  A. Levine,et al.  The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.

[99]  J. Manley,et al.  Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. , 2010, Cancer research.

[100]  D. da Silva,et al.  Regulation of mammalian muscle type 6‐phosphofructo‐1‐kinase and its implication for the control of the metabolism , 2010, IUBMB life.

[101]  H. Westerhoff,et al.  Metabolic control analysis indicates a change of strategy in the treatment of cancer. , 2010, Mitochondrion.

[102]  Wei-Shou Hu,et al.  Glucose metabolism in mammalian cell culture: new insights for tweaking vintage pathways. , 2010, Trends in biotechnology.

[103]  Jason W. Locasale,et al.  Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.

[104]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[105]  Mengwei Zang,et al.  AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. , 2010, Future oncology.

[106]  Marcel H. Schulz,et al.  Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments , 2010, Nucleic acids research.

[107]  S. Brunak,et al.  Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis , 2010, Science Signaling.

[108]  S. Snyder,et al.  H2S Signals Through Protein S-Sulfhydration , 2009, Science Signaling.

[109]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[110]  R. Moreno-Sánchez,et al.  HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. , 2009, Mini reviews in medicinal chemistry.

[111]  J. Lee,et al.  Enzymatic properties of the N- and C-terminal halves of human hexokinase II. , 2009, BMB reports.

[112]  V. Jain,et al.  Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. , 2009, Future oncology.

[113]  A. Yalçin,et al.  Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. , 2009, Experimental and molecular pathology.

[114]  D. Vriens,et al.  Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review , 2009, Journal of Nuclear Medicine.

[115]  J. Nitiss.  Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.

[116]  N. Hay,et al.  Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.

[117]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[118]  Julien Verrax,et al.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.

[119]  W. Weber,et al.  Tumor Cell Metabolism Imaging , 2008, Journal of Nuclear Medicine.

[120]  A. Merlo,et al.  Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death , 2008, Clinical Cancer Research.

[121]  M. Yerle,et al.  Assignment and expression patterns of porcine muscle-specific isoform of phosphoglycerate mutase gene. , 2008, Journal of genetics and genomics = Yi chuan xue bao.

[122]  Y. Elkina,et al.  Investigation of glyceraldehyde-3-phosphate dehydrogenase from human sperms , 2008, Biochemistry (Moscow).

[123]  Eunok Paek,et al.  Strategy for comprehensive identification of post-translational modifications in cellular proteins, including low abundant modifications: application to glyceraldehyde-3-phosphate dehydrogenase. , 2008, Journal of proteome research.

[124]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[125]  Johnathan C. Maher,et al.  Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. , 2007, Antioxidants & redox signaling.

[126]  G Jan,et al.  GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization , 2007, Oncogene.

[127]  Alexander Kamb,et al.  Why is cancer drug discovery so difficult? , 2007, Nature Reviews Drug Discovery.

[128]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[129]  B. Kahn,et al.  Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. , 2006, The Journal of clinical investigation.

[130]  R. Govindan,et al.  Novel formulations of taxanes: a review. Old wine in a new bottle? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  W. Zong,et al.  Chemotherapeutic approaches for targeting cell death pathways. , 2006, The oncologist.

[132]  N. Manes,et al.  The kinase activity of human brain 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is regulated via inhibition by phosphoenolpyruvate. , 2005, Archives of biochemistry and biophysics.

[133]  P. Chandra,et al.  MODELLING AND ANALYSIS OF THE SPREAD OF MALARIA: ENVIRONMENTAL AND ECOLOGICAL EFFECTS , 2005 .

[134]  C. Thompson,et al.  Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. , 2004, Molecular cell.

[135]  Karen N. Allen,et al.  Structure of human brain fructose 1,6‐(bis)phosphate aldolase: Linking isozyme structure with function , 2004, Protein science : a publication of the Protein Society.

[136]  Martin G Pomper,et al.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.

[137]  D. Vertommen,et al.  6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. , 2004, The Biochemical journal.

[138]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[139]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[140]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[141]  J. Caro,et al.  Hypoxic regulation of the 6‐phosphofructo‐2‐kinase/fructose‐2,6‐bisphosphatase gene family (PFKFB‐1–4) expression in vivo , 2003, FEBS letters.

[142]  K. Webster.  Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia , 2003, Journal of Experimental Biology.

[143]  John Eric Wilson.  Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function , 2003, Journal of Experimental Biology.

[144]  I. Barasoain,et al.  Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. , 2003, Current cancer drug targets.

[145]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[146]  L. Bertrand,et al.  Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. , 2002, Journal of molecular and cellular cardiology.

[147]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells , 2001, The Journal of Biological Chemistry.

[148]  H. Westerhoff,et al.  Transcriptome meets metabolome: hierarchical and metabolic regulation of the glycolytic pathway , 2001, FEBS letters.

[149]  R. Sakakibara,et al.  Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. , 1997, Journal of biochemistry.

[150]  B. Tribukait,et al.  Expression of glycolytic isoenzymes in activated human peripheral lymphocytes: cell cycle analysis using flow cytometry. , 1991, Experimental cell research.

[151]  C. V. van Veelen,et al.  Subunit composition, regulatory properties, and phosphorylation of phosphofructokinase from human gliomas. , 1987, Cancer research.

[152]  D. Knowles,et al.  Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy. , 1985, Cancer research.

[153]  F. Suzuki,et al.  Characterization of αα,ββ,γγ and αγ human enolase isozymes, and preparation of hybrid enolases (αγ,βγ and αβ) from homodimeric forms , 1983 .

[154]  P. Eagles,et al.  A comparative study of aldolase from human muscle and liver. , 1973, The Biochemical journal.

[155]  E. S. Younathan,et al.  Modulation of the kinetic properties of phosphofructokinase by ammonium ions. , 1971, The Journal of biological chemistry.

[156]  T. Jeffcoate.  DISORDERS OF MENSTRUATION , 1957 .

[157]  H. Eagle,et al.  Nutrition needs of mammalian cells in tissue culture. , 1955, Science.

[158]  A. Sols,et al.  The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds. , 1954, The Journal of biological chemistry.

[159]  P. Carmeliet,et al.  Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. , 2013, Trends in biochemical sciences.

[160]  R. Gillies,et al.  Targeting the metabolic microenvironment of tumors. , 2012, Advances in pharmacology.

[161]  Jiwon Kim,et al.  5-fluorouracil induced cardiotoxicity: review of the literature. , 2012, Cardiology journal.

[162]  K. Vousden,et al.  Control of glycolysis through regulation of PFK1: old friends and recent additions. , 2011, Cold Spring Harbor symposia on quantitative biology.

[163]  Wh Sit,et al.  Cancer Genomics & Proteomics , 2007 .

[164]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[165]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[166]  L. Alberghina,et al.  Systems Biology: Definitions and Perspectives , 2005 .

[167]  G. Dunaway,et al.  A review of animal phosphofructokinase isozymes with an emphasis on their physiological role , 2004, Molecular and Cellular Biochemistry.

[168]  R. Sakakibara,et al.  A common phosphorylation site for cyclic AMP-dependent protein kinase and protein kinase C in human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. , 1998, Bioscience, biotechnology, and biochemistry.

[169]  E. Pérez-Artés,et al.  Comparative kinetic behaviour and regulation by fructose-1,6-bisphosphate and ATP of pyruvate kinase from erythrocytes, reticulocytes and bone marrow cells. , 1987, Comparative biochemistry and physiology. B, Comparative biochemistry.